Axsome Therapeutics' 66% projected growth rate may be overly...

Axsome Therapeutics' 66% projected growth rate may be overly optimistic. A slower growth rate might push the break-even point further, and the high debt level of 63% of its equity amplifies the investment risk in the unprofitable company.